Prelude Capital Management’s CorMedix CRMD Stock Holding History

Prelude Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-20,011	Closed	-$233K	–	1278
2025 Q4	$233K	Buy	20,011 +4,421	+28%	+$48.9K	0.02%	954
2025 Q3	$181K	Buy	+15,590	New	+$188K	0.01%	973
2025 Q2	–	Sell	-14,810	Closed	-$91.2K	–	1059
2025 Q1	$91.2K	Buy	+14,810	New	+$153K	0.01%	1051
2017 Q4	–	Sell	-3,000	Closed	-$8K	–	1412
2017 Q3	$8K	Buy	+3,000	New	+$6.22K	﹤0.01%	1456

Other funds holding CRMD

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Prelude Capital Management's CRMD Position: Q1 2026 in Review

Prelude Capital Management sold out of CorMedix (CRMD) in Q1 2026, closing a stake of 20,011 shares — an estimated $233K sold.

Prelude Capital Management first reported a position in CRMD in Q3 2017 and held it in 4 quarters. The position peaked at $233K in Q4 2025. 188 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

Prelude Capital Management reported no remaining CorMedix position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 20,011 CorMedix shares in Q1 2026, an estimated $233K.
Prelude Capital Management first reported a position in CorMedix in Q3 2017 and held it in 4 quarters.
Prelude Capital Management's CorMedix position peaked at $233K in Q4 2025.
188 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.